• Clinical testing of AnlterA’s first-in class Norrin/Wnt-agonist antibody initiated through a strategic collaboration and licensing agreement with EyeBio
• Derived from ANT-Pharm platform, EYE103 is a Norrin/Wnt-agonist clinical antibody molecule developed by EyeBio in close collaboration with AntlerA for treatment of retinopathies
  

San Francisco, June 15^th, 2023 – Life Science Newswire – AntlerA Norrin/Wnt-agonist antibody through a strategic partnership with EyeBio enters clinical trials for treatment of retinopathies.

AntlerA previously reported the development of a Norrin/Wnt-mimetic for treatment of leaky blood vessels in the eye. 

“We are pleased to support EyeBio in the development and advancement of EYE103, a Norrin/Wnt-mimetic, into the clinic.  Built based on AntlerA’s ANT-Pharm platform the tetravalent antibody molecule binds specifically to FZD4/LRP5 receptors leading to Wnt-signaling and restoration of blood vessels integrity in the eye.” said Dr. Sekar Seshagiri, CEO, AntlerA Therapeutics.  He further added “This is a first-in class molecule for treatment of diabetic retinopathy and several pediatric retinal diseases such as FEVR/Norrie, Coats, and ROP”

About AntlerA Therapeutics, Inc.

AntlerA Therapeutics is a regenerative medicines company focused on developing novel protein therapeutics that function by modulating Wnt signaling to harness the regenerative potential of tissue resident stem cells.

For more information, please visit www.antlera.com